Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Carcinoma, Transitional Cell
Drug Resistance, Neoplasm
Neural Cell Adhesion Molecule L1
Urinary Bladder Neoplasms
This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.